Nav: Home

Journal of Comparative Effectiveness research discusses oncology treatment sequences

December 17, 2015

Future Science Group (FSG) today announced the publication of a new article in the Journal of Comparative Effectiveness Research, discussing the recent recommendations from the Center for Medical Technology Policy's (CMTP) Green Park Collaborative (GPC-USA). The recommendations, released in August, discuss the conduct of studies that compare sequences of therapies in areas of advanced and metastatic cancer where a range of therapeutic options exist, but evidence is lacking on the optimal choices for sequential or combination therapy.

As the article discusses, current preferences for treatment order are developed in ways that can be lengthy and inefficient. However, these decisions are crucial for the patient as they can influence the course of disease, patient quality of life and ultimately patient survival.

It was against this backdrop that the GPC-USA selected this as a priority topic. In a new editorial article, Dr Donna Messner, Vice President and Senior Research Director at the CMTP, and GPC-USA Oncology Consortium Lead, describes the framework the GPC-USA developed to address the challenge and their recommendations for more rapid assessment of the comparative effectiveness of oncology treatment sequences.

"The recommended approach can fill evidence gaps between traditional clinical trials, especially as real-world data sources become more robust. At the same time, it puts the spotlight on new kinds of patient-important outcomes that traditional trials largely have not measured; these types of outcomes are starting to be recognized as important." commented Donna Messner.

"The recommendations released by the GPC-USA in August provide a valuable resource for the oncology community, who are making difficult decisions regarding treatment sequences", commented Laura Dormer, Managing Editor of the Journal of Comparative Effectiveness Research. "We are delighted to feature an article discussing the recent recommendations and how they were developed, and look forward to seeing the further discussion they will inevitably generate."
The article is available free to read at:

About Journal of Comparative Effectiveness Research

The goal of comparative effectiveness research is to assist patients, physicians, purchasers and policymakers to choose between the available effective treatments in order to improve healthcare delivery at the level of the individual and on a population scale. The underlying question in undertaking comparative effectiveness research is - which treatment will work best, in which patient, and under what circumstances? Journal of Comparative Effectiveness Research (IF: 0.719), launched in 2012, provides stakeholders with the key data and opinions to make informed and specific decisions on clinical practice.

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.

Future Science Group

Related Metastatic Cancer Articles:

Metastatic breast cancer cells use hedgehog to 'evilize' docile neighbors
A University of Colorado Cancer Center study published today in Nature Communications shows that metastatic breast cancer cells signal neighboring cells in ways that allow otherwise anchored cells to metastasize.
Olaparib slows growth of BRCA-related metastatic breast cancer
Findings from a phase III clinical trial of about 300 women may introduce PARP inhibitors as a new type of treatment for breast cancer.
Immunotherapy drug effective for metastatic triple negative breast cancer
The immunotherapy drug, Pembrolizumab, is effective in shrinking tumors among metastatic triple negative breast cancer patients as found in a clinical trial led by NYU Langone's Perlmutter Cancer Center.
Study estimates number of US women living with metastatic breast cancer
A new study shows that the number of women in the United States living with distant metastatic breast cancer, the most severe form of the disease, is growing.
New type of PET imaging identifies primary and metastatic prostate cancer
In the featured article from the February 2017 issue of The Journal of Nuclear Medicine, researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment.
Metastatic pancreatic cancer 'reprogrammed' for malignancy
Metastatic pancreatic cancer -- cancer that has spread from the pancreas to other tissues and is responsible for most patient deaths -- changes its metabolism and is 'reprogrammed' for optimal malignancy, according to new findings reported Jan.
Researchers propose mechanism for spread of metastatic breast cancer to bone
New research explains how metastatic breast cancer cells might use bone marrow-derived mesenchymal stem cells (MSCs) to help them spread to bone tissue.
Custirsen shows no survival benefits in metastatic prostate cancer
A phase III randomized controlled trial of custirsen in combination with cabazitaxel/prednisone in patients with previously-treated metastatic, castration-resistant prostate cancer has shown no significant survival gains compared to cabazitaxel/prednisone alone, according to data presented at the ESMO 2016 Congress in Copenhagen
Nintedanib improves progression-free survival in metastatic colorectal cancer
Nintedanib improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to results of the phase III LUME-colon 1 trial presented at the ESMO 2016 Congress in Copenhagen.
Nivolumab reduces symptoms in relapsed metastatic head and neck cancer
Nivolumab maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial presented at the ESMO 2016 Congress in Copenhagen1 and published in the New England Journal of Medicine.

Related Metastatic Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".